Zimmer Biomet Holdings (ZBH) Tops Q1 EPS by 7c; Boosts FY16 Outlook

Go back to Zimmer Biomet Holdings (ZBH) Tops Q1 EPS by 7c; Boosts FY16 Outlook

Zimmer Biomet (ZBH) PT Raised to $134 at Needham & Company

April 28, 2016 1:46 PM EDT

Needham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on Zimmer Biomet (NYSE: ZBH) to $134.00 (from $129.00).

Matson commented, "ZBH beat consensus revenue and EPS in 1Q16 and management raised guidance. Pro forma constant currency revenue growth improved to... More